Skip to main content

Table 3 Pain and itching during acute phase according to the localization of lesions

From: Clinical spectrum and long-term outcomes of mpox: a cohort study spanning from acute infection to six-month follow-up

Localization of lesions

N

With pain

Risk ratio (95%-CI)

With itching

Risk ratio (95%-CI), p1

n

(%)

n

(%)

Genital

17

4

(23.5)

Reference

4

(23.5)

Reference

Anal

13

11

(84.6)

3.60 (1.48–8.74), p= 0.001

9

(69.2)

2.94 (1.16–7.46), p= 0.018

Mouth / Throat

9

6

(66.7)

2.83 (1.07–7.50), p= 0.047

2

(22.2)

0.94 (0.21–4.20), p = 0.964

Face / Neck

11

3

(27.3)

1.16 (0.32–4.21), p = 0.831

2

(18.2)

0.77 (0.17–3.53), p = 0.775

Torso

11

3

(27.3)

1.16 (0.32–4.21), p = 0.831

3

(27.3)

1.16 (0.32–4.21), p = 0.831

Extremities

13

3

(23.1)

0.98 (0.26–3.64), p = 0.986

5

(38.5)

1.63 (0.54–4.90), p = 0.413

  1. 1Obtained from Mid-P exact test